# Inulin Gut Microbiome Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/inulin-gut-microbiome-meta-analysis-evidence-review
Category: evidence-review
Summary: Inulin Gut Microbiome Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are sys
Last reviewed: 2026-06-14
Reviewed by: Migaku Evidence Review
# Inulin Gut Microbiome Meta-analysis: What the Evidence Says

## Quick Answer

Inulin Gut Microbiome Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| The Efficacy of Gut Microbiome–Modulating Therapies on Liver Cirrhosis: A Systematic Review and Network Meta-Analysis | systematic review | 1 | 2026-05-01 | 10.14309/ctg.0000000000001010 |
| Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation | narrative review | 3 | 2026-05-30 | 10.3390/nu18111765 |

## What The Sources Report

- The most common causes associated with LC are hepatitis C, followed by alcohol consumption, hepatitis B, and metabolic liver diseases. [Wang Yi (2026); evidence level 1]
- Research indicates that LC is associated with significant intestinal barrier dysfunction, which parallels the progression of the disease. [Wang Yi (2026); evidence level 1]
- Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the dominant form of chronic liver disease worldwide and should be understood not as an isolated hepatic disorder but as a liver-centred expression of systemic metabolic dysfunction. [Acierno Carlo (2026); evidence level 3]
- Epidemiological data indicate that MASLD patients carry a significantly elevated risk of incident type 2 diabetes, a cardiovascular risk that exceeds liver-related mortality in many cohorts, and a meaningful lifetime risk of hepatocellular carcinoma even in the absence of cirrhosis-underscoring the systemic clinical consequences of the condition. [Acierno Carlo (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For inulin gut microbiome meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Wang Yi (2026). The Efficacy of Gut Microbiome–Modulating Therapies on Liver Cirrhosis: A Systematic Review and Network Meta-Analysis. DOI: 10.14309/ctg.0000000000001010. PMCID: PMC13193310. PMID: 41778620. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-Non Commercial-No Derivatives License.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13193310/
- Acierno Carlo (2026). Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation. DOI: 10.3390/nu18111765. PMCID: PMC13258734. PMID: 42280407. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13258734/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.